CEACAM5 and cancer: A number of scholars pointed out that CRC could acquire cibisatamab-resistance via gradual loss of CEAs on cancer cells since PDOs with high expression level of CEA exhibited high level of drug sensitivity, while PDOs with low expression level of CEA were found resistant to cibisatamab (70).